NCT06308419View on ClinicalTrials.gov

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

February 1, 2029

Study Completion Date

February 1, 2031

Conditions
LeiomyosarcomaSoft-tissue Sarcomas
Interventions
DRUG

Gemcitabine

Given by IV

DRUG

Nab-Sirolimus

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Aadi Bioscience
All Listed Sponsors
collaborator

Aadi Bioscience

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT06308419 - A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | Biotech Hunter | Biotech Hunter